Analysts expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will report sales of $15.93 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings. The highest sales estimate is $20.10 million and the lowest is $13.80 million. Agios Pharmaceuticals posted sales of $11.36 million during the same quarter last year, which suggests a positive year-over-year growth rate of 40.2%. The business is expected to issue its next earnings report on Wednesday, November 7th.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full-year sales of $85.36 million for the current year, with estimates ranging from $81.93 million to $95.10 million. For the next financial year, analysts forecast that the company will post sales of $111.32 million per share, with estimates ranging from $79.28 million to $140.50 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($1.62) by $0.43. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The firm had revenue of $40.40 million for the quarter, compared to the consensus estimate of $12.47 million. During the same quarter last year, the company earned ($1.78) earnings per share. The business’s revenue for the quarter was up 257.5% compared to the same quarter last year.
Several research analysts have recently commented on the company. Piper Jaffray Companies set a $125.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. BidaskClub downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Needham & Company LLC reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Thursday, August 2nd. ValuEngine downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 11th. Finally, Citigroup assumed coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They issued a “buy” rating and a $117.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $97.90.
In related news, insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $83.50, for a total transaction of $250,500.00. Following the sale, the insider now owns 60,196 shares of the company’s stock, valued at approximately $5,026,366. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Steven L. Hoerter sold 2,050 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, June 22nd. The shares were sold at an average price of $97.58, for a total value of $200,039.00. Following the sale, the insider now directly owns 2,050 shares in the company, valued at approximately $200,039. The disclosure for this sale can be found here. Insiders have sold a total of 30,677 shares of company stock worth $2,412,335 in the last three months. 3.02% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of AGIO. Lord Abbett & CO. LLC raised its stake in Agios Pharmaceuticals by 175.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock valued at $85,407,000 after purchasing an additional 665,684 shares during the period. Baillie Gifford & Co. bought a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $47,607,000. BlackRock Inc. increased its stake in Agios Pharmaceuticals by 14.0% in the 1st quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock worth $262,192,000 after acquiring an additional 393,336 shares during the last quarter. Woodford Investment Management Ltd bought a new stake in Agios Pharmaceuticals in the 2nd quarter worth approximately $32,849,000. Finally, Wells Fargo & Company MN increased its stake in Agios Pharmaceuticals by 459.8% in the 2nd quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock worth $34,315,000 after acquiring an additional 334,617 shares during the last quarter. 93.64% of the stock is currently owned by institutional investors.
NASDAQ AGIO opened at $73.44 on Friday. Agios Pharmaceuticals has a 52 week low of $51.62 and a 52 week high of $99.82. The stock has a market capitalization of $4.30 billion, a PE ratio of -10.88 and a beta of 1.77.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Read More: Marijuana Stocks Future Looks Bright
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.